Phase 3 ARANOTE Study of ADT + Darolutamide: Safety

Evan Y. Yu, MD, discusses how safety data for first-line androgen deprivation therapy plus androgen receptor pathway inhibitors (ARPI) regimens such as darolutamide, abiraterone, enzalutamide, and apalutamide reveal clinically relevant distinctions in their safety profiles, including the most common and challenging toxicities, incidence of grade 3 or higher adverse events, treatment discontinuations, and potential drug-drug interactions. He highlights key factors that influence treatment choice and disease management in patients with metastatic hormone-sensitive prostate cancer.